1. Background {#sec1}
=============

Meibomian gland dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands. It is commonly characterized by obstruction of the terminal ducts and qualitative and/or quantitative changes in glandular secretions \[[@B1]\]. These can cause changes in tear film, eye irritation, clinically apparent inflammation, and diseases of the ocular surface \[[@B2]\].

MGD can be divided into low-delivery and high-delivery states based on meibomian gland secretions. Obstructive MGD is the most common form of dry eye and is categorized as a low-delivery state \[[@B2]\]. It is also a major cause of evaporative dry eye disease. In this condition, decreased delivery of meibum to the ocular surface causes increased tear evaporation. The resulting increase in tear film osmolality leads to ocular surface damage \[[@B3]\].

Eyelid hygiene is essential in the management of MGD and plays a fundamental role in decreasing the load of lipolytic bacteria and the amount of potentially toxic lipids on the ocular surface originating from products that cause tear film spoilage (e.g., free fatty acids) \[[@B4]--[@B8]\]. Several lid scrubs are commercially available and have been shown to be effective for managing dry eye disease \[[@B7]--[@B11]\]. Baby shampoo is one such lid scrub and for many physicians is the treatment of choice for chronic blepharitis. However, even though it is gentle and pH-balanced, ocular surface irritation can still occur when this conventional shampoo contacts the ocular surface.

In this study, we investigated a novel eyelid shampoo formulated for lid hygiene regimens. This shampoo is nonirritating and potentially lengthens the eyelashes. The purpose of this study was to evaluate the effects of this newly developed eye-cleansing formulation on MGD and eyelash length.

2. Material and Methods {#sec2}
=======================

The study protocol was prospectively reviewed and approved by the Minamiaoyama Eye Clinic Internal Review Board and was conducted according to the tenets of the Declaration of Helsinki. All subjects provided written informed consent to participate after receiving a detailed explanation of the study.

2.1. Subjects {#sec2.1}
-------------

Ten patients (2 men, 8 women) with dry eye associated with MGD were enrolled into the study. The patients in the MGD-related dry eye group were diagnosed according to the 2006 guidelines published by Shimazaki \[[@B12]\]. To determine whether the trial shampoo (Eye Shampoo Long \[ESL\], MediProduct Co., Ltd., Tokyo, Japan) had an effect on eyelash growth, we included 10 healthy subjects (4 men, 6 women) for measurement of eyelash length.

2.2. Eyelid Hygiene Product {#sec2.2}
---------------------------

ESL is a nonirritating, eye-cleansing formulation ([Figure 1(a)](#fig1){ref-type="fig"}) with a pH of 7.4 and an osmolality of 300 mOsm/L, which is similar to that of normal tear film \[[@B13]\]. The product contains components that are anti-inflammatory (dipotassium glycyrrhizate, cholecalciferol \[vitamin D3\]) and moisturizing (blends of ceramide, Kjellmaniella gyrate extract) and promote hair growth (cholecalciferol \[vitamin D3\], Panax ginseng root extract, Kjellmaniella gyrate extract, and amino acids (see [Table 1](#tab1){ref-type="table"} )) \[[@B14]--[@B19]\]. The manufacturer confirmed product safety.

All participants used ESL twice a day for 8 weeks according to the prescribed study washing regimen, which entailed pumping the shampoo onto one hand or a piece of cotton and spreading it gently around the eyes. Next, the study participants lightly massaged their eyelids to remove impurities located at the eyelash roots and rinsed their eyes with water ([Figure 1(b)](#fig1){ref-type="fig"}). During the study, subjects were asked to continue any eye drops that they were using at enrollment.

2.3. Study Tests and Examinations {#sec2.3}
---------------------------------

Examinations were performed in 10 patients with MGD-associated dry eye and in 10 healthy subjects to check for a possible effect on eyelash growth. The characteristics of the two groups are presented in [Table 2](#tab2){ref-type="table"}. All subjects completed a background survey ([Table 3](#tab3){ref-type="table"}) at the time of enrollment (baseline) and at the end of the 8-week treatment period.

The examinations ([Table 4](#tab4){ref-type="table"}) included tear breakup time, fluorescein staining score, and lipid layer thickness (LipiView, TearScience, Inc., Morrisville, NC, USA). Eyelid margin findings (meibomian gland blockage, eyelash contamination, eyelid margin foam, and decreased meibum secretion) were graded on a 5-point scale ranging from 0 to 4 ([Table 5](#tab5){ref-type="table"}). The change in meibum secretion was evaluated by extruding meibum from the lower eyelid using MGE-100 (TearScience, Inc.). The severity of superficial punctate keratopathy (SPK) was evaluated using a 4-point scale ranging from 0 to 3. The corneal surface was divided into nasal, temporal, and central regions, and SPK was graded in each area. The final SPK score was calculated as the sum of all regional scores. Visual acuity, intraocular pressure (IOP), and refractive error were measured at each study visit. The longest eyelash on the left eye was identified, pulled, and taped to a piece of paper for measurement.

Dry eye symptoms were evaluated using a questionnaire administered at baseline and after 8 weeks of using ESL. The questionnaire assessed 17 ocular symptoms ([Table 6](#tab6){ref-type="table"}). Responses of "none," "mild," "moderate," and "severe" were scored as 0, 1, 2, and 3, respectively.

2.4. Statistical Analyses {#sec2.4}
-------------------------

The data are presented as the mean ± standard deviation. Differences in subjective symptoms and findings at the eyelid margin (meibomian gland blockage, eyelash contamination, lid margin foam, and decreased meibum secretion) were tested for statistical significance using the Mann---Whitney *U* test. Differences in ocular surface findings (including SPK) and eyelash length were tested for statistical significance using the Wilcoxon signed rank test. Statistical significance was defined as *p* \< .05.

3. Results {#sec3}
==========

3.1. Subjective Symptoms {#sec3.1}
------------------------

The patients with MGD showed a significant improvement from baseline in subjective symptoms after 8 weeks using ESL. Sensation of dryness, bleary eyes (foreign body sensation), grittiness (foreign body sensation), sore eyes (burning sensation), and heat (burning sensation) improved significantly (*p* \< .05) during this time ([Table 7](#tab7){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}).

3.2. Findings at the Eyelid Margin {#sec3.2}
----------------------------------

Patients with MGD showed a significant improvement (*p* \< .05) in meibomian gland blockage, eyelash contamination, and eyelid margin foam, as well as decreased meibum secretion ([Table 7](#tab7){ref-type="table"}, Figures [3](#fig3){ref-type="fig"} [](#fig4){ref-type="fig"} [](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}).

3.3. Eyelash Growth {#sec3.3}
-------------------

Eyelashes were significantly longer after 8 weeks of using ESL than they were at baseline in the patients with MGD and in the healthy subjects (*p* \< .05; [Table 7](#tab7){ref-type="table"}, [Figure 7](#fig7){ref-type="fig"}).

3.4. Ocular Surface and Tear Function {#sec3.4}
-------------------------------------

SPK significantly improved in the MGD group (*p* \< .05) during the 8-week study period. However, no significant changes were observed in tear breakup time or lipid layer thickness this time ([Table 7](#tab7){ref-type="table"}, [Figure 8](#fig8){ref-type="fig"}).

4. Discussion {#sec4}
=============

Our results indicate that the condition of the eyelids improved markedly after using ESL for 8 weeks. The objective findings for MGD and the ocular surface improved, subjective dry eye symptoms (e.g., chronic ocular discomfort) lessened, and eyelash length increased.

It was suspected that ESL would not be effective because a mild shampoo is likely to have limited cleansing ability. However, we found improvements in the cleanliness of the eyelashes and meibomian blockage.

In general, lid hygiene regimens consist of application of warm compresses and lid massage to clear meibomian gland blockage. Antibiotics and anti-inflammatory agents can also be used to improve the quality of the meibum. Tear substitutes and additional lubricants can help to alleviate the symptoms of dry eye. Topical antibiotic ointments may be used in moderate and severe cases. However, the treatments available have somewhat variable effects and must be continued over long periods to achieve a satisfactory reduction of symptoms. As a result, patients often discontinue treatment \[[@B6], [@B7]\].

The patients in this study were compliant with the lid hygiene regimen partly because of improvements in their MGD symptoms, such as eyelash contamination, and subjective symptoms. ESL is believed to improve compliance because the regimen is less complicated than that required when using conventional baby shampoo regimens; for example, unlike baby shampoo, this product does not need to be diluted. No treatments for MGD that are effective in long-term use have been described in the literature. However, ESL is easy to handle and reduces irritation; therefore patients using it may be more likely to continue their treatment.

The eyelash-lengthening effect of ESL maybe due to its vitamin D and hair growth-promoting components and/or the effects of better hygiene \[[@B14], [@B15]\]. It is possible that lengthening of the eyelashes occurred once the eyelashes were cleaned by washing and the condition of the eyelash roots improved. Therefore, future studies should compare ESL with other formulations to investigate this effect. The mRNA encoding 25-hydroxylase, the vitamin D activation enzyme, was recently shown to be present in some ocular cells \[[@B16]\]. However, expression of this gene in the meibomian glands of epithelial cells has not been confirmed. It is possible that vitamin D~3~ is activated in the meibomian gland epithelium and induces eyelash growth, as has been demonstrated on the scalp \[[@B14]--[@B16], [@B17]\]. Future studies should be performed to determine whether the vitamin D activation enzyme is expressed in the epithelium of the meibomian glands. Lastly, lid massage may have promoted eyelash growth because of the presence of Panax ginseng extract and Kjellmaniella gyrate extract, both of which are known to stimulate hair growth \[[@B18], [@B19]\].

The effect of ESL on lid hygiene was similar to that of already available commercial products \[[@B4]\]. However, ESL is less irritating and has the additional benefit of lengthening the eyelashes. The lash-lengthening effect of ESL may further improve compliance with the lid hygiene regimen and encourage patients with MGD to wash their eyelids regularly, just as they brush their teeth. ESL can also be used as a make-up remover, so it can reduce MGD caused by residual eye make-up.

In the present study, no adverse events such as redness, discharge, pupillary formation of congestive, and edema were observed and good results were obtained using ESL. Moreover, no participants reported irritation using ESL. Previous report admitted product safety \[[@B4]\]. In addition, participants reported that ESL was easily available and that they felt reduced MGD symptoms and 30% of the subjects continue to use the ESL. These suggest that continued use of ESL could have additional favorable effects on the meibomian gland; however, we have to admit that the sample size is small. Further investigation is warranted \[[@B4]\].

In summary, ESL is the first product in Japan which can take care of eyelashes as well as MGD treatment. ESL effectively improved the signs and symptoms of MGD and lengthened eyelashes, which may encourage patients to continue using the product. Both of these factors would encourage compliance with a lid hygiene regimen.
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###### 

Composition of Eye Shampoo Long.

                         INCI code                     Function
  ---------------------- ----------------------------- -------------------------
  1                      Water                         Base
  2                      Butylene glycol               Moisturizer
  Content less than 1%                                 
  3                      Alanine                       Moisturizer
  4                      Allantoin                     Moisturizer
  5                      Arginine                      pH adjuster
  6                      Carbomer                      Thickener
  7                      Ceramide AP                   Emollient
  8                      Ceramide EOP                  Emollient
  9                      Ceramide NP                   Emollient
  10                     Cholecalciferol               Emollient
  11                     Cholesterol                   Emollient
  12                     Citric acid                   pH adjuster
  13                     Dipotassium glycyrrhizinate   Skin-conditioning agent
  14                     Disodium guanylate            Moisturizer
  15                     Disodium inosinate            Moisturizer
  16                     Glutamic acid                 Moisturizer
  17                     Glycine                       Moisturizer
  18                     Histidine HCl                 Moisturizer
  19                     Isoleucine                    Moisturizer
  20                     Kjellmaniellagyrata extract   Moisturizer
  21                     Leucine                       Moisturizer
  22                     Lysine HCl                    Moisturizer
  23                     Panax ginseng root extract    Moisturizer
  24                     PEG-25 glyceryl isostearate   Detergent
  25                     Phenoxyethanol                Preservative
  26                     Phenylalanine                 Moisturizer
  27                     Phytic acid                   Chelating agent
  28                     Phytosphingosine              Emollient
  29                     Proline                       Moisturizer
  30                     Sericin                       Moisturizer
  31                     Serine                        Moisturizer
  32                     Silver oxide                  Preservative
  33                     Sodium aspartate              Moisturizer
  34                     Sodium chloride               Base
  35                     Sodium lauroyl lactylate      Moisturizer
  36                     Sodium polyacrylate           Thickener
  37                     Taurine                       Moisturizer
  38                     Threonine                     Moisturizer
  39                     Tyrosine                      Moisturizer
  40                     Valine                        Moisturizer
  41                     Xanthan gum                   Thickener
  42                     Zea mays (corn) oil           Emollient

###### 

Demographic characteristics of study participants.

  ---------------------------------------------------------
  Parameter     MGD patients\   Controls, eyelash length\
                (*n* = 10)      (*n* = 10)
  ------------- --------------- ---------------------------
  Male          2               4

  Female        8               6

  Age (years)   53.8 (32--79)   34.0 (34--54)
  ---------------------------------------------------------

###### 

Questionnaire of eye care habits.

                                    Yes   No   Occasionally   Hardly ever
  --------------------------------- ----- ---- -------------- -------------
  Use of contact lens                                          
  Anamnesis of LASIK                                           
  Regular eye washing                                          
  Anamnesis of stye and chalazion                              
  Use of eye drops                                             

###### 

Specialized and nonspecialized tests for meibomian gland dysfunction, dry eye, and eyelash length.

  Category                           Test
  ---------------------------------- ------------------------------
  Symptoms                           Original questionnaires^*∗*^
  Signs                               
  Meibomian function                 Eye lash contamination
  Meibomian gland blockage           
  Eyelid margin foam                 
  Decreased meibum secretion         
  Ocular surface                     Tear breakup time
  Superficial punctate keratopathy   
  Lipid layer thickness              
  Eyelash                            Length

^*∗*^See [Table 5](#tab5){ref-type="table"} for grading scales.

###### 

Grading scales for signs of meibomian gland dysfunction.

  --------------------------------- ----------------------------------------
  *Eyelash contamination*           
  0                                 Clear
  1                                 Slight contamination
  2                                 Mild
  3                                 Moderate
  4                                 Severe
                                    
  *Meibomian orifice obstruction*   
  0                                 Clear liquid
  1                                 Yellowish liquid
  2                                 Opaque and toothpaste-like consistency
  3                                 Thickened white material
  4                                 Not possible
                                    
  *Meibomian gland blockage*        
  0                                 None
  1                                 \<25% blocked glands
  2                                 25% to \<50%
  3                                 50% to \<75%
  4                                 75% or more
                                    
  *Lid margin foam*                 
  0                                 Clear
  1                                 At the canthus
  2                                 Lower or upper
  3                                 Lower and upper
  4                                 Lower and upper or at the canthus
  --------------------------------- ----------------------------------------

###### 

Results of ocular symptoms questionnaire before and after 8 weeks of the study intervention.

                                                             0 (none)   1 (mild)   2 (moderate)   3 (severe)
  ---------------------------------------------------------- ---------- ---------- -------------- ------------
  \(1\) Eye discomfort (vague discomfort in eyes)                                                  
  \(2\) Sensations of dryness                                                                      
  \(3\) Bleary eyes (foreign body sensation)                                                       
  \(4\) Grittiness (foreign body sensation)                                                        
  \(5\) Sore eyes (burning sensation)                                                              
  \(6\) Heat (burning sensation)                                                                   
  \(7\) Eye discharge (gum in eye)                                                                 
  \(8\) Stringy mucus                                                                              
  \(9\) Blurriness                                                                                 
  \(10\) Eye strain                                                                                
  \(11\) Eye pain                                                                                  
  \(12\) Lacrimation (excessive watering of the eye)                                               
  \(13\) Itchiness                                                                                 
  \(14\) Red eye                                                                                   
  \(15\) Heaviness                                                                                 
  \(16\) Extra sensitivity to light                                                                
  \(17\) Excessive frequent eye blinking (frequent blinks)                                         

###### 

Comparison of symptoms, meibomian gland function, eyelash length, and ocular surface according to treatment group (we listed the items with *p* \< .05 only).

  ------------------------------------------------------------------------------------------------------------------------
  Group/task                          Baseline\                                 8 weeks\      *p* versus baseline   
                                      (mean ± SD)                               (mean ± SD)                         
  ----------------------------------- ----------------------------------------- ------------- --------------------- ------
  *Subjective symptoms*                                                                                             

                                      Sensation of dryness                      2.20 ± 0.63   1.80 ± 0.79           .046

                                      Bleary eyes (foreign body sensation)      1.90 ± 0.74   1.10 ± 0.57           .011

                                      Gritty feeling (foreign body sensation)   1.90 ± 1.10   1.20 ± 0.92           .020

                                      Sore eyes (burning sensation)             1.80 ± 0.63   0.70 ± 0.67           .009

                                      Heat (burning sensation)                  0.60 ± 0.70   0.20 ± 0.63           .046

                                                                                                                    

  *Meibomian gland function*                                                                                        

                                      Eyelash contamination                     0.70 ± 0.86   0.00 ± 0.00           .004

                                      Meibomian gland blockage                  3.40 ± 0.68   2.45 ± 0.69           .000

                                      Eyelid margin foam                        0.20 ± 0.41   0.00 ± 0.00           .046

                                      Decreased meibum secretion                1.40 ± 0.82   0.80 ± 0.52           .038

                                                                                                                    

  *Eyelash length*                                                                                                  

  MGD patients and healthy subjects   Length                                    8.13 ± 1.80   8.84 ± 1.86           .020

                                                                                                                    

  *Ocular surface*                                                                                                   

                                      Superficial punctate keratopathy          2.95 ± 2.25   1.75 ± 1.77           .002
  ------------------------------------------------------------------------------------------------------------------------

MGD: meibomian gland dysfunction; SD: standard deviation.
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